Benthic fluxes in a tropical Estuary and their role in the ecosystem

In-situ measurements of benthic fluxes of oxygen and nutrients were made in the subtidal region of the Mandovi estuary during premonsoon and monsoon seasons to understand the role of sediment-water exchange processes in the estuarine ecosystem. The Mandovi estuary is a shallow, highly dynamic, macrotidal estuary which experiences marine condition in the premonsoon season and nearly fresh water condition in the monsoon season. The benthic flux of nutrients exhibited strong seasonality, being higher in the premonsoon compared to the monsoon season which explains the higher ecosystem productivity in the dry season in spite of negligible riverine nutrient input. NH4+ was the major form of released N comprising 70-100% of DIN flux. The benthic respiration rate varied from -98.91 to -35.13 mmol m-2 d-1, NH4+ flux from 5.15 to 0.836 mmol m-2 d-1, NO3- + NO2- from 0.06 to -1.06 mmol m-2 d-1, DIP from 0.12 to 0.23 mmol m-2 d-1 and SiO44- from 5.78 to 0.41 mmol m-2 d-1 between premonsoon to monsoon period. The estuarine sediment acted as a net source of DIN in the premonsoon season, but changed to a net sink in the monsoon season. Variation in salinity seemed to control NH4+ flux considerably. Macrofaunal activities, especially bioturbation, enhanced the fluxes 2-25 times. The estuarine sediment was observed to be a huge reservoir of NH4+, PO43- and SiO44- and acted as a net sink of combined N because of the high rate of benthic denitrification as it could remove 22% of riverine DIN influx thereby protecting the eco system from eutrophication and consequent degradation. The estuarine sediment was responsible for ~30-50% of the total community respiration in the estuary. The benthic supply of DIN, PO43- and SiO44- can potentially meet 49%, 25% and 55% of algal N, P and Si demand, respectively, in the estuary. Based on these observations we hypothesize that it is mainly benthic NH4+ efflux that sustains high estuarine productivity in the NO3- depleted dry season

STABILITY-INDICATING VALIDATED REVERSED PHASE-HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR SIMULTANEOUS DETERMINATION OF COBICISTAT AND ATAZANAVIR SULFATE IN BULK AND PHARMACEUTICAL DOSAGE FORM

ABSTRACTObjective: A simple, rapid, precise, accurate, and economical stability-indicating reversed phase-high performance liquid assay method was developedand validated for simultaneous estimation of cobicistat (COB) and atazanavir (ATV) sulfate in bulk drugs and their combined commercial tablets.Methods: The method has shown adequate separation of COB and ATV from their degradation products. Separation was achieved on a LunaCN (250 mm × 4.6 mm, 5 μm column at a detection wavelength of 239 nm) using a mobile phase consists of o-phthaldialdeyde (Ph2.5) IX buffer,acetonitrile, and methanol in the ratio of 40:40:20 in an isocratic elution mode at a flow rate of 1 ml/min. Results: The retention times for COB and ATV sulfate were found to be 3.606 and 6.113 min, respectively. COB and ATV sulfate, their combinationdrug product was subjected to acid, base, neutral hydrolysis, thermal, and photolytic stress conditions. Thus, stressed samples were analyzed by theproposed analytical method. Validation of the proposed analytical method was carried out as per ICH guidelines Q2R1. Quantitation was achievedwith UV detection at 239 nm based on peak area with linear calibration curves at concentration ranges 50-600 μg/ml for COB and 100-1200 μg/ml forATV sulfate (R2 = 0.999 for both drugs). The limits of detection were 0.25 μg/ml and 0.5 μg/ml for COB and ATV sulfate, respectively. Conclusion: The method was found to be specific and stability indicating as no interfering peaks of degradants and excipients were observed. Theproposed method is hence suitable for application in quality-control laboratories for quantitative analysis of both the drugs individually and incombination dosage forms since it is simple and rapid with good accuracy and precision.Keywords: Stability-indicating assay, Reversed phase-high performance liquid, Cobicistat, Atazanavir sulfate, Forced degradation studies

MENCA experiment aboard India’s Mars Orbiter Mission

The Mars Exospheric Neutral Composition Analyser (MENCA) aboard the Indian Mars Orbiter Mission (MOM) is a quadrupole mass spectrometer-based experiment. Making use of the highly elliptical and low inclination (~150°) orbit of MOM, MENCA will conduct in situ measurements of the composition and radial distribution of the Martian neutral exosphere in the 1–300 amu mass range in the equatorial and low latitudes of Mars. The functionality of MENCA has been tested during the Earth-bound and heliocentric phases of MOM before its operation in the Martian orbit. This article describes the scientific objectives, instrument details, design and development, test and evaluation, and calibration of the MENCA instrument

Survey of green mussel seed resources of Kerala and Karnataka

Farming of marine mussels Is practiced extensively in the temperate and Southeast Asian countries. In India two species of mussels, Perna viridis and Perna indica commonly known as the green and brown mussels respectively have been reported

Understanding our seas: National Institute of Oceanography, Goa

The present article summarizes the research done at the CSIR–National Institute of Oceanography in 2014 in ocean science, resources and technology. Significant research has been conducted on air–sea interactions and coastal circulation, biogeochemistry, biology, marine geophysics, palaeoceanography, marine fishery, gas hydrates and wave energy. Technological advances covered topics like oceanographic tools. Major strides have been made in marine resources research and evaluation

Understanding our seas: National Institute of Oceanography, Goa

The present article summarizes the research done at the CSIR–National Institute of Oceanography in 2014 in ocean science, resources and technology. Significant research has been conducted on air–sea interactions and coastal circulation, biogeochemistry, biology, marine geophysics, palaeoceanography, marine fishery, gas hydrates and wave energy. Technological advances covered topics like oceanographic tools. Major strides have been made in marine resources research and evaluation

Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017 : a systematic analysis for the Global Burden of Disease Study 2017

Background Previous attempts to characterise the burden of chronic respiratory diseases have focused only on specific disease conditions, such as chronic obstructive pulmonary disease (COPD) or asthma. In this study, we aimed to characterise the burden of chronic respiratory diseases globally, providing a comprehensive and up-to-date analysis on geographical and time trends from 1990 to 2017. Methods Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, we estimated the prevalence, morbidity, and mortality attributable to chronic respiratory diseases through an analysis of deaths, disability-adjusted life-years (DALYs), and years of life lost (YLL) by GBD super-region, from 1990 to 2017, stratified by age and sex. Specific diseases analysed included asthma, COPD, interstitial lung disease and pulmonary sarcoidosis, pneumoconiosis, and other chronic respiratory diseases. We also assessed the contribution of risk factors (smoking, second-hand smoke, ambient particulate matter and ozone pollution, household air pollution from solid fuels, and occupational risks) to chronic respiratory disease-attributable DALYs. Findings In 2017, 544.9 million people (95% uncertainty interval [UI] 506.9- 584.8) worldwide had a chronic respiratory disease, representing an increase of 39.8% compared with 1990. Chronic respiratory disease prevalence showed wide variability across GBD super-regions, with the highest prevalence among both males and females in high-income regions, and the lowest prevalence in sub-Saharan Africa and south Asia. The age-sex- specific prevalence of each chronic respiratory disease in 2017 was also highly variable geographically. Chronic respiratory diseases were the third leading cause of death in 2017 (7.0% [95% UI 6.8-7 .2] of all deaths), behind cardiovascular diseases and neoplasms. Deaths due to chronic respiratory diseases numbered 3 914 196 (95% UI 3 790 578-4 044 819) in 2017, an increase of 18.0% since 1990, while total DALYs increased by 13.3%. However, when accounting for ageing and population growth, declines were observed in age-standardised prevalence (14.3% decrease), agestandardised death rates (42.6%), and age-standardised DALY rates (38.2%). In males and females, most chronic respiratory disease-attributable deaths and DALYs were due to COPD. In regional analyses, mortality rates from chronic respiratory diseases were greatest in south Asia and lowest in sub-Saharan Africa, also across both sexes. Notably, although absolute prevalence was lower in south Asia than in most other super-regions, YLLs due to chronic respiratory diseases across the subcontinent were the highest in the world. Death rates due to interstitial lung disease and pulmonary sarcoidosis were greater than those due to pneumoconiosis in all super-regions. Smoking was the leading risk factor for chronic respiratory disease-related disability across all regions for men. Among women, household air pollution from solid fuels was the predominant risk factor for chronic respiratory diseases in south Asia and sub-Saharan Africa, while ambient particulate matter represented the leading risk factor in southeast Asia, east Asia, and Oceania, and in the Middle East and north Africa super-region. Interpretation Our study shows that chronic respiratory diseases remain a leading cause of death and disability worldwide, with growth in absolute numbers but sharp declines in several age-standardised estimators since 1990. Premature mortality from chronic respiratory diseases seems to be highest in regions with less-resourced health systems on a per-capita basis

Global, regional, and national burden of neurological disorders, 1990–2016 : a systematic analysis for the Global Burden of Disease Study 2016

Background: Neurological disorders are increasingly recognised as major causes of death and disability worldwide. The aim of this analysis from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 is to provide the most comprehensive and up-to-date estimates of the global, regional, and national burden from neurological disorders. Methods: We estimated prevalence, incidence, deaths, and disability-adjusted life-years (DALYs; the sum of years of life lost [YLLs] and years lived with disability [YLDs]) by age and sex for 15 neurological disorder categories (tetanus, meningitis, encephalitis, stroke, brain and other CNS cancers, traumatic brain injury, spinal cord injury, Alzheimer's disease and other dementias, Parkinson's disease, multiple sclerosis, motor neuron diseases, idiopathic epilepsy, migraine, tension-type headache, and a residual category for other less common neurological disorders) in 195 countries from 1990 to 2016. DisMod-MR 2.1, a Bayesian meta-regression tool, was the main method of estimation of prevalence and incidence, and the Cause of Death Ensemble model (CODEm) was used for mortality estimation. We quantified the contribution of 84 risks and combinations of risk to the disease estimates for the 15 neurological disorder categories using the GBD comparative risk assessment approach. Findings: Globally, in 2016, neurological disorders were the leading cause of DALYs (276 million [95% UI 247–308]) and second leading cause of deaths (9·0 million [8·8–9·4]). The absolute number of deaths and DALYs from all neurological disorders combined increased (deaths by 39% [34–44] and DALYs by 15% [9–21]) whereas their age-standardised rates decreased (deaths by 28% [26–30] and DALYs by 27% [24–31]) between 1990 and 2016. The only neurological disorders that had a decrease in rates and absolute numbers of deaths and DALYs were tetanus, meningitis, and encephalitis. The four largest contributors of neurological DALYs were stroke (42·2% [38·6–46·1]), migraine (16·3% [11·7–20·8]), Alzheimer's and other dementias (10·4% [9·0–12·1]), and meningitis (7·9% [6·6–10·4]). For the combined neurological disorders, age-standardised DALY rates were significantly higher in males than in females (male-to-female ratio 1·12 [1·05–1·20]), but migraine, multiple sclerosis, and tension-type headache were more common and caused more burden in females, with male-to-female ratios of less than 0·7. The 84 risks quantified in GBD explain less than 10% of neurological disorder DALY burdens, except stroke, for which 88·8% (86·5–90·9) of DALYs are attributable to risk factors, and to a lesser extent Alzheimer's disease and other dementias (22·3% [11·8–35·1] of DALYs are risk attributable) and idiopathic epilepsy (14·1% [10·8–17·5] of DALYs are risk attributable). Interpretation: Globally, the burden of neurological disorders, as measured by the absolute number of DALYs, continues to increase. As populations are growing and ageing, and the prevalence of major disabling neurological disorders steeply increases with age, governments will face increasing demand for treatment, rehabilitation, and support services for neurological disorders. The scarcity of established modifiable risks for most of the neurological burden demonstrates that new knowledge is required to develop effective prevention and treatment strategies. Funding: Bill & Melinda Gates Foundation

The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019

BACKGROUND: Communicable disease control has long been a focus of global health policy. There have been substantial reductions in the burden and mortality of communicable diseases among children younger than 5 years, but we know less about this burden in older children and adolescents, and it is unclear whether current programmes and policies remain aligned with targets for intervention. This knowledge is especially important for policy and programmes in the context of the COVID-19 pandemic. We aimed to use the Global Burden of Disease (GBD) Study 2019 to systematically characterise the burden of communicable diseases across childhood and adolescence. METHODS: In this systematic analysis of the GBD study from 1990 to 2019, all communicable diseases and their manifestations as modelled within GBD 2019 were included, categorised as 16 subgroups of common diseases or presentations. Data were reported for absolute count, prevalence, and incidence across measures of cause-specific mortality (deaths and years of life lost), disability (years lived with disability [YLDs]), and disease burden (disability-adjusted life-years [DALYs]) for children and adolescents aged 0-24 years. Data were reported across the Socio-demographic Index (SDI) and across time (1990-2019), and for 204 countries and territories. For HIV, we reported the mortality-to-incidence ratio (MIR) as a measure of health system performance. FINDINGS: In 2019, there were 3·0 million deaths and 30·0 million years of healthy life lost to disability (as measured by YLDs), corresponding to 288·4 million DALYs from communicable diseases among children and adolescents globally (57·3% of total communicable disease burden across all ages). Over time, there has been a shift in communicable disease burden from young children to older children and adolescents (largely driven by the considerable reductions in children younger than 5 years and slower progress elsewhere), although children younger than 5 years still accounted for most of the communicable disease burden in 2019. Disease burden and mortality were predominantly in low-SDI settings, with high and high-middle SDI settings also having an appreciable burden of communicable disease morbidity (4·0 million YLDs in 2019 alone). Three cause groups (enteric infections, lower-respiratory-tract infections, and malaria) accounted for 59·8% of the global communicable disease burden in children and adolescents, with tuberculosis and HIV both emerging as important causes during adolescence. HIV was the only cause for which disease burden increased over time, particularly in children and adolescents older than 5 years, and especially in females. Excess MIRs for HIV were observed for males aged 15-19 years in low-SDI settings. INTERPRETATION: Our analysis supports continued policy focus on enteric infections and lower-respiratory-tract infections, with orientation to children younger than 5 years in settings of low socioeconomic development. However, efforts should also be targeted to other conditions, particularly HIV, given its increased burden in older children and adolescents. Older children and adolescents also experience a large burden of communicable disease, further highlighting the need for efforts to extend beyond the first 5 years of life. Our analysis also identified substantial morbidity caused by communicable diseases affecting child and adolescent health across the world. FUNDING: The Australian National Health and Medical Research Council Centre for Research Excellence for Driving Investment in Global Adolescent Health and the Bill & Melinda Gates Foundation

Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: A systematic analysis for the global burden of disease study 2017

© 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Background: Previous attempts to characterise the burden of chronic respiratory diseases have focused only on specific disease conditions, such as chronic obstructive pulmonary disease (COPD) or asthma. In this study, we aimed to characterise the burden of chronic respiratory diseases globally, providing a comprehensive and up-to-date analysis on geographical and time trends from 1990 to 2017. Methods: Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, we estimated the prevalence, morbidity, and mortality attributable to chronic respiratory diseases through an analysis of deaths, disability-adjusted life-years (DALYs), and years of life lost (YLL) by GBD super-region, from 1990 to 2017, stratified by age and sex. Specific diseases analysed included asthma, COPD, interstitial lung disease and pulmonary sarcoidosis, pneumoconiosis, and other chronic respiratory diseases. We also assessed the contribution of risk factors (smoking, second-hand smoke, ambient particulate matter and ozone pollution, household air pollution from solid fuels, and occupational risks) to chronic respiratory disease-attributable DALYs. Findings: In 2017, 544·9 million people (95% uncertainty interval [UI] 506·9–584·8) worldwide had a chronic respiratory disease, representing an increase of 39·8% compared with 1990. Chronic respiratory disease prevalence showed wide variability across GBD super-regions, with the highest prevalence among both males and females in high-income regions, and the lowest prevalence in sub-Saharan Africa and south Asia. The age-sex-specific prevalence of each chronic respiratory disease in 2017 was also highly variable geographically. Chronic respiratory diseases were the third leading cause of death in 2017 (7·0% [95% UI 6·8–7·2] of all deaths), behind cardiovascular diseases and neoplasms. Deaths due to chronic respiratory diseases numbered 3 914 196 (95% UI 3 790 578–4 044 819) in 2017, an increase of 18·0% since 1990, while total DALYs increased by 13·3%. However, when accounting for ageing and population growth, declines were observed in age-standardised prevalence (14·3% decrease), age-standardised death rates (42·6%), and age-standardised DALY rates (38·2%). In males and females, most chronic respiratory disease-attributable deaths and DALYs were due to COPD. In regional analyses, mortality rates from chronic respiratory diseases were greatest in south Asia and lowest in sub-Saharan Africa, also across both sexes. Notably, although absolute prevalence was lower in south Asia than in most other super-regions, YLLs due to chronic respiratory diseases across the subcontinent were the highest in the world. Death rates due to interstitial lung disease and pulmonary sarcoidosis were greater than those due to pneumoconiosis in all super-regions. Smoking was the leading risk factor for chronic respiratory disease-related disability across all regions for men. Among women, household air pollution from solid fuels was the predominant risk factor for chronic respiratory diseases in south Asia and sub-Saharan Africa, while ambient particulate matter represented the leading risk factor in southeast Asia, east Asia, and Oceania, and in the Middle East and north Africa super-region. Interpretation: Our study shows that chronic respiratory diseases remain a leading cause of death and disability worldwide, with growth in absolute numbers but sharp declines in several age-standardised estimators since 1990. Premature mortality from chronic respiratory diseases seems to be highest in regions with less-resourced health systems on a per-capita basis. Funding: Bill & Melinda Gates Foundation